Central Trust Co buys $21,795,800 stake in Pfizer (PFE)

Pfizer (PFE) : Central Trust Co scooped up 27,461 additional shares in Pfizer during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Apr 11, 2016. The investment management firm now holds a total of 670,640 shares of Pfizer which is valued at $21,795,800.Pfizer makes up approximately 1.70% of Central Trust Co’s portfolio.

Pfizer closed down -0.15 points or -0.46% at $32.5 with 3,52,74,322 shares getting traded on Friday. Post opening the session at $32.65, the shares hit an intraday low of $32.3 and an intraday high of $32.785 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.

Other Hedge Funds, Including , Dnb Asset Management As boosted its stake in PFE in the latest quarter, The investment management firm added 388,300 additional shares and now holds a total of 2,526,392 shares of Pfizer which is valued at $82,107,740. Pfizer makes up approx 1.69% of Dnb Asset Management As’s portfolio.Kistler-tiffany Companies boosted its stake in PFE in the latest quarter, The investment management firm added 654 additional shares and now holds a total of 40,169 shares of Pfizer which is valued at $1,280,989. Pfizer makes up approx 0.72% of Kistler-tiffany Companies’s portfolio.Foundry Partners boosted its stake in PFE in the latest quarter, The investment management firm added 40,258 additional shares and now holds a total of 688,908 shares of Pfizer which is valued at $21,969,276. Pfizer makes up approx 2.20% of Foundry Partners’s portfolio.Baystate Wealth Management boosted its stake in PFE in the latest quarter, The investment management firm added 17 additional shares and now holds a total of 28,155 shares of Pfizer which is valued at $897,863. Pfizer makes up approx 0.20% of Baystate Wealth Management’s portfolio.Private Asset Management Inc boosted its stake in PFE in the latest quarter, The investment management firm added 1,328 additional shares and now holds a total of 565,456 shares of Pfizer which is valued at $18,032,392. Pfizer makes up approx 3.29% of Private Asset Management Inc’s portfolio.

On the company’s financial health, Pfizer reported $0.53 EPS for the quarter, beating the analyst consensus estimate by $ 0.17 according to the earnings call on Feb 2, 2016. Analyst had a consensus of $0.36. The company had revenue of $14047.00 million for the quarter, compared to analysts expectations of $13595.19 million. The company’s revenue was up 7.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.54 EPS.

Many Wall Street Analysts have commented on Pfizer. JP Morgan Resumed Pfizer on Apr 7, 2016 to “Overweight”, Price Target of the shares are set at $38.Morgan Stanley Resumed Pfizer on Apr 7, 2016 to “Equal-Weight”, Price Target of the shares are set at $35.

Pfizer Inc. is a global biopharmaceutical company. The Company is engaged in discovering developing and manufacturing of healthcare products. Its products include Lyrica the Prevnar family of products Enbrel Celebrex Lipitor Viagra Zyvox Sutent EpiPen Toviaz Tygacil Rapamune Xalkori Inlyta Norvasc BeneFIX Genotropin and Enbrel among others. It operates in three segments: Global Innovative Pharmaceutical segment (GIP) Global Vaccines Oncology and Consumer Healthcare segment (VOC) and Global Established Pharmaceutical segment (GEP). GIP is focused on developing registering and commercializing medications in therapeutic areas such as inflammation cardiovascular/metabolic neuroscience and pain rare diseases and women’s/men’s health. VOC focuses on the development and commercialization of vaccines and products for oncology and consumer healthcare. GEP includes its sterile injectable products and bio similar development portfolio. Its subsidiary is Hospira Inc.

Leave a Reply

Pfizer - Is it time to Sell?

Top Brokerage Firms are advising their investors on Pfizer. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.